Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (Western University)
- Development stage
- Unknown
- Lead developer
- Lawson Health Research Institute
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbial transplant (Western University) is an investigational live biotherapeutic product for the treatment of unexplained atherosclerosis. It is being studied in a Phase 1 clinical trial (NCT04410003) at Western University, Canada, led by Principal Investigator J. David Spence. The therapy involves the administration of fecal microbiota harvested from healthy donors who exhibit a 'Protected phenotype'—individuals with high levels of traditional risk factors for atherosclerosis but who have not developed the disease. The goal is to repopulate the gut microbiome of patients suffering from severe unexplained atherosclerosis to alter its composition and metabolic output. The primary mechanism is to reduce the production of pro-atherogenic metabolites, such as trimethylamine N-oxide (TMAO) and p-cresylsulfate, with the long-term goal of developing a cultured ecosystem of bacteria as a therapeutic for atherosclerosis.
- Other names
- fecal microbial transplantfecal microbiota transplant
Beyond the preview
Go deeper on fecal microbiota transplant (Western University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (Western University).